SecBot SecBot
SECBOTREPLAY Home › Report › NVS

NVS · The PTAB granted institution of IPR2026-00260, allowing Amneal and…

NOVARTIS AG · PTAB-TRIAL filed Nov 9, 2026 at 19:00 ET

At the news

NEUTRALIMPACT 3/10

PTAB-TRIAL filed Nov 9, 2026 at 19:00 ET

The PTAB granted institution of IPR2026-00260, allowing Amneal and Kashiv to challenge claims of Novartis's patent covering anti-IgE antibody therapy for multiple food allergies. As an interlocutory ruling, no claims have been cancelled, and the patent remains in force pending a final written decision.

  • PTAB granted institution of IPR2026-00260 on November 10, 2026
  • Patent U.S. 12030959 covers anti-IgE antibody therapy for multiple food allergies
  • Patent owner is Genentech Inc. and Novartis Pharmaceuticals Corp. (Novartis AG subsidiary)
  • Petitioners are Amneal Pharmaceuticals, Inc. and Kashiv Biosciences, LLC

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access